James Anderson and Jonathan Trott, who have given impressive performances against India, have been given rest in England's one-day squad, which will face India.
Anderson, bowler and batsman Trott have been replaced by Chris Woakes and Jos Buttler. It has been said that the two players, who have shown their best performance sides during test series played against India will be taking rest, so that they are full ready for series to be played against New Zealand and Australia.
As said, Woakes and Buttler have been called to play five matches of 50 over matches. The series is going to start in Rajkot from January 11.
Among others, who will be part of the series, are Joe Root and Eoin Morgan. Root has shown a great performance in Nagpur and that might be the reason his entry in the series.
The England and Wales Cricket Board (ECB) was the one, which announced that Anderson and Trott have been given rest. "Woakes and Buttler replace Anderson and Trott in [the] India ODI squad as [the] selectors look to manage workloads", said the board officials. Experts said that it is a great time for Woakes and Buttler to show their worth for the team.
According to a post published to Microsoft’s official blog on Wednesday, the number of devices running the company’s latest Windows version -- the Windows 10 operating system -- has touched 350 million.
The new milestone in the Windows 10...
A new study by the Massachusetts Institute of Technology (MIT) has revealed that Istanbul lies...
During the course of Thursday proceedings in the ongoing legal scuffle between Google and Oracle...
The Verge has revealed in a Wednesday report, citing a statement released by Lexus, that the working of the head units of a number of vehicles has been affected because of an over-the-air (OTA) update recently rolled out by the company.
...
The drought conditions in California is widening economic split in California. The prospect of...
Tech giant Google posted a video of a developer presentation to the Google Developers YouTube...
German drugmaker Merck said that its experimental cancer medicine evofosfamidehas failed in the last stage of clinical tests due to which it won't seek regulatory approval for its treatment.
On Monday, Darmstadt, Germany-based Merck said...
A panel of US medical experts said that there is no...
At the GSMA Mobile World Congress in Shanghai, HTV Vive...
According to a post published to Microsoft’s official...
No matter how dangerous a task it seems to look within a...
© 2011 AustrianTribune - Tribune Online Services. All times CET (GMT + 1.00).